Skip to contentC
Cytosorbents Corp
C
CTSOCytosorbents Corp Q3 2017 · 10-Q
Revenue$3.82M$3.82M+58.6% vs Q3 2016 Net Income-$2.05M-$2.05MN/M vs Q3 2016 EPS Diluted-$0.07-$0.07N/M vs Q3 2016 Gross Profit$2,307,435+59.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytosorbents Corp · CIK 1175151 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,183,352N/M Free Cash Flowderived-$2,533,677N/M Margins · derivedGross margin60.3%+0.3 pt vs Q3 2016
Operating margin-56.2%+32.7 pt vs Q3 2016
Net margin-53.7%+37.0 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end